Edgewise Therapeutics Sells Muscular Dystrophy Business to Servier for Up to \$2.65 Billion
BOULDER, Colo., June 1, 2026 – Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, has announced a transformative agreement to sell its muscular dystrophy business—including all rights to its lead asset, sevasemten—to Servier, an international pharmaceutical group, for a total potential consideration of up to \$2.65 billion.
Key Transaction Details
- Upfront cash consideration: \$1.55 billion
- Additional milestone payments: Up to \$1.1 billion (regulatory and commercial milestones)
- Total potential value: \$2.65 billion
- Closing timeline: Expected in Q3 2026, subject to regulatory and customary closing conditions
Strategic Impact for Edgewise Therapeutics
- Balance Sheet Strengthening: The upfront proceeds are expected to fully fund the development of Edgewise’s lead cardiovascular candidate, EDG-7500, through potential approval. This provides enhanced financial flexibility and removes funding risks for the company’s strategic pipeline.
-
Focus Shift: Following the transaction, Edgewise will become a cardiovascular-focused company, centering its strategy on its cardiac pipeline. The company’s portfolio will include:
- EDG-7500 (hypertrophic cardiomyopathy, HCM) – Phase 2 trial ongoing
- EDG-15400 (heart failure with preserved ejection fraction, HFpEF) – Phase 1 trial ongoing, Phase 2 expected to initiate in 2026
- EDG-003 (undisclosed cardiovascular target)
- Employee Transition: All Edgewise employees primarily supporting the muscular dystrophy business will receive comparable offers from Servier, ensuring continuity in research and development.
About Sevasemten and Muscular Dystrophy Business
- Sevasemten: An orally administered, first-in-class fast skeletal myosin inhibitor designed to mitigate muscle damage caused by loss of functional dystrophin. It is being studied in late-stage clinical trials for Becker and Duchenne muscular dystrophies.
- Clinical Evidence: Sevasemten has shown sustained disease stabilization for over three years in clinical studies, with participants maintaining stable North Star Ambulatory Assessment (NSAA) scores and a favorable safety profile (no discontinuations or dose reductions due to adverse events).
-
Regulatory Progress: Sevasemten has received:
- FDA Orphan Drug Designation for Becker and Duchenne
- Rare Pediatric Disease Designation (RPDD) for Duchenne
- Fast Track designations for Becker and Duchenne
- EMA Orphan Drug Designations for both indications
- Pivotal Trial: The GRAND CANYON pivotal cohort in Becker muscular dystrophy is fully enrolled (175 participants, powered >98%), with top-line data expected in Q4 2026.
Upcoming Milestones and Pipeline Updates
- EDG-7500: Edgewise plans to report 12-week Part D data from the CIRRUS-HCM Phase 2 trial in Q2 2026 (safety, echocardiographic, biomarker, patient-reported outcomes for both obstructive and non-obstructive HCM). This will inform Phase 3 trial design, targeted for initiation in Q4 2026.
- EDG-15400: Phase 2 trial in HFpEF expected to start in parallel with EDG-7500 advancement.
- Financial Outlook: The company expects the upfront proceeds from the transaction, combined with its existing cash, to fully fund EDG-7500 through potential approval and enable expansion of its pipeline.
Shareholder Considerations and Potential Price Sensitivity
- Large Upfront Cash Infusion: The \$1.55 billion upfront payment significantly de-risks Edgewise’s financial position and eliminates the need for near-term capital raises, which could be highly price sensitive.
- Strategic Shift: By divesting its muscular dystrophy business, Edgewise is now a pure-play cardiovascular company, which may impact investor perceptions, risk profiles, and valuation multiples.
- Milestone Payments: Up to \$1.1 billion in additional milestones provide further upside potential, subject to regulatory and commercial success.
- Potential for Share Price Movement: The scale of the transaction, the strategic realignment, and the removal of funding risk for EDG-7500 are all likely to be material and could move the share price substantially.
- Risks: The transaction is subject to regulatory approvals and customary closing conditions; any delays or failure to close could impact the share price. Ongoing clinical risks and pipeline execution remain relevant.
Advisors and Closing
Centerview Partners LLC acted as exclusive financial advisor to Edgewise, and Wilson Sonsini Goodrich & Rosati served as legal counsel. The boards of both Edgewise Therapeutics and Servier have unanimously approved the transaction. Edgewise and Servier expect the deal to close in the third quarter of 2026, pending regulatory approvals.
Forward-Looking Statements Disclaimer
This article contains forward-looking statements regarding the sale of Edgewise’s muscular dystrophy business, expected financial impacts, pipeline development, and regulatory milestones. Actual results may differ materially due to risks and uncertainties, including regulatory delays, clinical trial outcomes, competitive factors, and operational execution. Investors should review Edgewise’s filings with the U.S. Securities and Exchange Commission for detailed risk factors. This article is for informational purposes only and does not constitute investment advice.
